- Home
- EVM vs MGNX Comparison
EVM vs MGNX Comparison
Compare EVM & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVM
- MGNX
- Stock Information
- Founded
- EVM 2002
- MGNX 2000
- Country
- EVM United States
- MGNX United States
- Employees
- EVM N/A
- MGNX N/A
- Industry
- EVM Finance/Investors Services
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- EVM Finance
- MGNX Health Care
- Exchange
- EVM Nasdaq
- MGNX Nasdaq
- Market Cap
- EVM 228.0M
- MGNX 257.3M
- IPO Year
- EVM N/A
- MGNX 2013
- Fundamental
- Price
- EVM $9.31
- MGNX $3.00
- Analyst Decision
- EVM
- MGNX Hold
- Analyst Count
- EVM 0
- MGNX 10
- Target Price
- EVM N/A
- MGNX $7.17
- AVG Volume (30 Days)
- EVM 55.8K
- MGNX 496.5K
- Earning Date
- EVM 01-01-0001
- MGNX 03-06-2025
- Dividend Yield
- EVM 4.01%
- MGNX N/A
- EPS Growth
- EVM N/A
- MGNX N/A
- EPS
- EVM 0.20
- MGNX N/A
- Revenue
- EVM N/A
- MGNX $141,329,000.00
- Revenue This Year
- EVM N/A
- MGNX $174.73
- Revenue Next Year
- EVM N/A
- MGNX N/A
- P/E Ratio
- EVM $47.61
- MGNX N/A
- Revenue Growth
- EVM N/A
- MGNX 16.68
- 52 Week Low
- EVM $7.67
- MGNX $2.95
- 52 Week High
- EVM $9.59
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- EVM 47.98
- MGNX 37.54
- Support Level
- EVM $9.20
- MGNX $3.00
- Resistance Level
- EVM $9.35
- MGNX $3.22
- Average True Range (ATR)
- EVM 0.09
- MGNX 0.17
- MACD
- EVM 0.00
- MGNX -0.02
- Stochastic Oscillator
- EVM 56.92
- MGNX 7.69
About EVM Eaton Vance California Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance California Municipal Bond Fund is an investment company with an objective to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in its specified state. The company provides its solutions to individual investors, institutional investors, high net worth individuals, family office investors, and financial professionals. It offers a range of equity, income, and alternative strategies to institutional investors, both in the United States and internationally.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).